Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Tomm34 is commonly expressed in epithelial ovarian cancer and associates with tumour type and high FIGO stage

P. Muller, PJ. Coates, R. Nenutil, F. Trcka, R. Hrstka, J. Chovanec, V. Brychtova, B. Vojtesek,

. 2019 ; 12 (1) : 30. [pub] 20190327

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19034686

Grant support
ADOPT BBMRI-ERIC No. 676550 Horizon 2020
GACR 16-07321S Grantová Agentura České Republiky
NPS I - LO1413 Ministerstvo Školství, Mládeže a Tělovýchovy
LM2015089 Ministerstvo Školství, Mládeže a Tělovýchovy
DRO - MMCI 00209805 Ministerstvo Zdravotnictví Ceské Republiky

BACKGROUND: Increased activity of the chaperones Hsp70 and Hsp90 is a common feature of solid tumours. Translocase of the outer mitochondrial membrane 34 (Tomm34) is a cochaperone of both Hsp70 and Hsp90 that was found to be overexpressed in colorectal, hepatocellular, lung and breast carcinomas. The expression profile of Tomm34 in ovarian cancer has not been investigated. Therefore, the aim of the current study was to investigate the expression pattern of Tomm34 in ovarian carcinomas and analyse its correlation with clinico-pathological parameters. RESULTS: Epithelial ovarian cancers (140) were histologically classified based on their morphology and graded into two types comprising 5 histologic subgroups. Type I carcinomas comprise low grade serous (LGSC), clear cell (CCOC) and endometrioid (ENOC), type II comprises high grade serous carcinomas (HGSC) and solid, pseudoendometrioid, transitional carcinomas (SET). Tomm34 was more highly expressed in type II than type I carcinomas (p < 0.0001). Comparing tumours based on the mutation in the TP53 gene revealed similar results, where mutant tumours exhibited significantly higher levels of Tomm34 (p < 0.0001). The decreased levels of Tomm34 in type I carcinomas were particularly evident in clear cell and mucinous carcinomas. The expression of Tomm34 was also positively correlated with FIGO stage (r = 0.23; p = 0.007). Tomm34 levels also indicated poor prognosis for patients with mutant p53. CONCLUSIONS: Our data indicate that Tomm34 is commonly expressed at high levels in epithelial ovarian cancers, except for the clear cell and mucinous subtypes. The expression of Tomm34 corresponds with the dualistic model of ovarian cancer pathogenesis where high grade, type II tumours exhibit higher expression of Tomm34 in contrast to type I tumours. These data are also comparable to the previous findings that Tomm34 is a marker of progression and poor prognosis in human cancer.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19034686
003      
CZ-PrNML
005      
20191031103939.0
007      
ta
008      
191007s2019 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13048-019-0498-0 $2 doi
035    __
$a (PubMed)30917858
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Muller, Petr $u Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic.
245    10
$a Tomm34 is commonly expressed in epithelial ovarian cancer and associates with tumour type and high FIGO stage / $c P. Muller, PJ. Coates, R. Nenutil, F. Trcka, R. Hrstka, J. Chovanec, V. Brychtova, B. Vojtesek,
520    9_
$a BACKGROUND: Increased activity of the chaperones Hsp70 and Hsp90 is a common feature of solid tumours. Translocase of the outer mitochondrial membrane 34 (Tomm34) is a cochaperone of both Hsp70 and Hsp90 that was found to be overexpressed in colorectal, hepatocellular, lung and breast carcinomas. The expression profile of Tomm34 in ovarian cancer has not been investigated. Therefore, the aim of the current study was to investigate the expression pattern of Tomm34 in ovarian carcinomas and analyse its correlation with clinico-pathological parameters. RESULTS: Epithelial ovarian cancers (140) were histologically classified based on their morphology and graded into two types comprising 5 histologic subgroups. Type I carcinomas comprise low grade serous (LGSC), clear cell (CCOC) and endometrioid (ENOC), type II comprises high grade serous carcinomas (HGSC) and solid, pseudoendometrioid, transitional carcinomas (SET). Tomm34 was more highly expressed in type II than type I carcinomas (p < 0.0001). Comparing tumours based on the mutation in the TP53 gene revealed similar results, where mutant tumours exhibited significantly higher levels of Tomm34 (p < 0.0001). The decreased levels of Tomm34 in type I carcinomas were particularly evident in clear cell and mucinous carcinomas. The expression of Tomm34 was also positively correlated with FIGO stage (r = 0.23; p = 0.007). Tomm34 levels also indicated poor prognosis for patients with mutant p53. CONCLUSIONS: Our data indicate that Tomm34 is commonly expressed at high levels in epithelial ovarian cancers, except for the clear cell and mucinous subtypes. The expression of Tomm34 corresponds with the dualistic model of ovarian cancer pathogenesis where high grade, type II tumours exhibit higher expression of Tomm34 in contrast to type I tumours. These data are also comparable to the previous findings that Tomm34 is a marker of progression and poor prognosis in human cancer.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádorové biomarkery $x genetika $x metabolismus $7 D014408
650    _2
$a epiteliální ovariální karcinom $x metabolismus $x patologie $7 D000077216
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a lidé středního věku $7 D008875
650    _2
$a transportní proteiny mitochondriální membrány $x metabolismus $7 D033681
650    _2
$a mutace $7 D009154
650    _2
$a staging nádorů $7 D009367
650    _2
$a nádory vaječníků $x metabolismus $x patologie $7 D010051
650    _2
$a prognóza $7 D011379
650    _2
$a nádorový supresorový protein p53 $x genetika $7 D016159
655    _2
$a časopisecké články $7 D016428
700    1_
$a Coates, Philip J $u Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic.
700    1_
$a Nenutil, Rudolf $u Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic.
700    1_
$a Trcka, Filip $u Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic.
700    1_
$a Hrstka, Roman $u Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic.
700    1_
$a Chovanec, Josef $u Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic.
700    1_
$a Brychtova, Veronika $u Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic.
700    1_
$a Vojtesek, Borivoj $u Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic. vojtesek@mou.cz.
773    0_
$w MED00200602 $t Journal of ovarian research $x 1757-2215 $g Roč. 12, č. 1 (2019), s. 30
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30917858 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191031104419 $b ABA008
999    __
$a ok $b bmc $g 1451346 $s 1073236
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 12 $c 1 $d 30 $e 20190327 $i 1757-2215 $m Journal of ovarian research $n J Ovarian Res $x MED00200602
GRA    __
$a ADOPT BBMRI-ERIC No. 676550 $p Horizon 2020
GRA    __
$a GACR 16-07321S $p Grantová Agentura České Republiky
GRA    __
$a NPS I - LO1413 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a LM2015089 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a DRO - MMCI 00209805 $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20191007

Find record

Citation metrics

Archiving options